|Hwang's Patented Fraud and |
New Questions about STAP Cells , Biopolitical TimesFebruary 19th, 2014Hwang Woo-suk is awarded a U.S. patent based on the work for which he was disgraced almost a decade ago; an investigation is launched into some apparently similar errors in the recent STAP cell papers.
|Company Patenting Tech for Designing Babies[With CGS's Marcy Darnovsky], KTVUNovember 20th, 2013Biotechnology may give parents unprecedented choices. Fertility clinics already use pre-implantation genetic diagnosis to select traits for some in-vitro babies, but intentional manipulation might create ethical nightmares.|
|Designing Children, Genomics Law ReportNovember 12th, 2013Some degree of mastery over the genetic future of the human species seems to be a possibility. For whom and for what does this technology exist?|
|NIH Seeks Comments on Plan to Share Genomic Data, Biopolitical TimesNovember 7th, 2013The National Institutes of Health is accepting public comments until November 20 on a draft Genomic Data Sharing Policy that promotes the wide-scale sharing of human and non-human genomic data.|
|23andMe's Designer Baby Patent, Huffington PostOctober 4th, 2013Even if 23andMe doesn't bring its donor selection technique to market, a patent award sends the message that this is an invention whose development should be protected and promoted.|
|Your Body, Their Property, Boston ReviewSeptember 30th, 2013When the U.S. Supreme Court struck down human gene patents it took one aspect of the debate over property interests in human biological materials off the table. But other body parts are still considered fair game.|
|Corporate Genetics, Technology ReviewAugust 21st, 2013In June the U.S. Supreme Court ruled that patents on genes were invalid. Yet corporate intellectual-property claims can still harm patients.|
|DTC Monopoly and Me, Biopolitical TimesAugust 6th, 2013A recent study shows yet again that results from different direct-to-consumer genetic testing companies vary. So what will the emerging monopoly of 23andMe mean for accuracy?
|Myriad Ruling Causes Confusion, NatureJune 18th, 2013The Supreme Court decision ended a long-running, emotionally charged legal challenge to gene patents, but the grey area between this ruling and the court’s second point — that patents can be claimed on modified DNA — has puzzled observers.|
|Reactions to the Supreme Court Ruling Against Myriad, Biopolitical TimesJune 13th, 2013The unanimous Supreme Court decision that human genes may not be patented was greeted with enthusiasm by the large coalition of plaintiffs and supporters, while the losers tried to put a brave face on it.|
|Cancer Inc., Biopolitical TimesMay 28th, 2013Angelina Jolie’s widely discussed op-ed about her preventative double mastectomy glosses over the impact of one company’s patent on the “breast cancer genes” as well as alternative choices that are available to women who have mastectomies.
|Can Human Genes Be Patented?, ScienceApril 17th, 2013The question has been debated for years but not addressed directly by the U.S. Supreme Court—until this week. The decision, expected later this year and from which there is no appeal, could have an impact on hundreds of companies and thousands of researchers.|
|Can We Patent Life?, The New YorkerApril 2nd, 2013Jonas Salk would not be amused, but if the Supreme Court buys Myriad’s argument, the sun, along with the carbon, hydrogen, and oxygen contained within it, will indeed be up for grabs, and so will every gene in our bodies.|
|Moore is LessWhy the Development of Pluripotent Stem Cells Might Lead Us to Rethink Differential Property Interests in Excised Human Cells, Stanford Technology Law ReviewJanuary 15th, 2013A proposal for addressing the profound legal issues raised by induced pluripotent stem cells.|
|The Definitive Book on the Strange History of BiDil, Biopolitical TimesDecember 6th, 2012Jonathan Kahn's new Race In A Bottle is an extraordinary account of the birth, life, and death(?) of the first drug to receive FDA approval for a specific racial group.|
|European Society of Human Genetics Reprimands Myriad Genetics, Biopolitical TimesNovember 7th, 2012Myriad Genetics claims its research data is a trade secret as it pushes for a stronger presence in the European genetic testing market. Experts' responses reflect the ideological divide in the ongoing challenge to Myriad's BRCA gene patents.|
|Human Genes - Sold to the Highest Bidder?Federal Appeals Court Ruled that Myriad Can in Fact Patent Isolated Human Genes
, Biopolitical TimesAugust 23rd, 2012A U.S. federal appeals court has reaffirmed that gene patents are legal in its ruling last week that Myriad Genetics can keep its patent on the BRCA1 and BRCA2 genes.|
|Patients Seek Stem-Cell Compensation, Nature NewsJuly 6th, 2012Six patients in California are suing RNL Bio, one of the world’s largest stem-cell companies, for allegedly misleading them about the effectiveness of its stem-cell treatments.|
|Pride: In Your Genes? , Biopolitical TimesJune 28th, 2012A new "gay gene" study and a strange float at the Pride Parade present a context to reflect on genetic determinism and the meaning of pride. |
|Gene Patent Case Ramps Up, Nature News BlogJune 15th, 2012The ACLU has filed additional documents in its lawsuit challenging patents on DNA in preparation for a hearing next month by a federal appeals court.
|Rewritable Memory Encoded into DNA, NatureMay 21st, 2012Researchers in California have successfully encoded a type of rewritable memory into bacterial DNA. However, it took three years and over 750 attempts to do so, demonstrating the difficulty of coding apparently simple processes into DNA.
|Prometheus: Bound. Myriad: Condemned?, Biopolitical TimesMarch 26th, 2012The Supreme Court has asked a lower court to reconsider its ruling in the Myriad Genetics gene patent case, in light of the High Court’s recent decision to invalidate Prometheus Laboratories’ patents.
|Can a Company Own Your Genes?, Mother JonesDecember 15th, 2011Last Wednesday, the American Civil Liberties Union petitioned the Supreme Court to rule on whether Myriad Genetics' patenting of the BRCA1 and BRCA2 genes is a sound legal practice.|
|Life, MonetizedDeadly Monopolies: The Shocking Corporate Takeover of Life Itself — And the Consequences for Your Health and Our Medical Future, by Harriet A. Washington, The American ProspectNovember 17th, 2011Harriet Washington's new book examines the ways in which the “medical-industrial complex” benefits research industries at the expense of both consumers and human research subjects.|
|Geron Quits the Embryonic Stem Cell Industry, Biopolitical TimesNovember 16th, 2011Geron has cancelled its clinical trial of a stem-cell treatment for spinal cord injuries, raising questions about the future of the company and the industry.|
|UK Supreme Court Upholds Gene Patent, BioNewsNovember 14th, 2011In what appears to be the end of a long-running legal saga, the UK's Supreme Court found in favor of a patent for a gene and the protein sequence it encodes.
|Myriad’s Molecular Monopoly to Face the Nine, Biopolitical TimesOctober 20th, 2011The American Civil Liberties Union and the Public Patent Foundation will petition the Supreme Court to rule on the legality of Myriad Genetics’ patents on cancer-related genes. |
|Race and bio-patents don't mix, Biopolitical TimesAugust 3rd, 2011The Washington Post ran a piece drawing heavily on Jonathan Kahn's recent work, which examines how US patent procedure is forcing race into genetic and medical research.
|The Myriad Breast Cancer Patent Case Continues, Biopolitical TimesAugust 1st, 2011A federal appeals court mostly overturned the lower court ruling that invalidated Myriad's patents on breast cancer genes, but further appeals are expected.|
|Ruling Upholds Gene Patent in Cancer Test, New York TimesJuly 29th, 2011The Court of Appeals for the Federal Circuit, which specializes in patent cases, said that Myriad Genetics was entitled to patents on two human genes used to predict if women have an increased risk of getting breast and ovarian cancer.|
|A Near-Miss on Gene Patents in Congress, Biopolitical TimesJune 23rd, 2011A House bill seeking to work around the harms of gene patents may inadvertently threaten ongoing efforts toward a ban, many advocacy and medical groups worry. |
|Doctor Abandons US Patent Application[Solomon Islands]Solomon Times April 11th, 2011The Network of the Indigenous Peoples-Solomons welcomes the abandonment of a US patent application that uses genetic samples from Solomon Islanders, in a case that raises major ethical questions.|
|More Arguing About Human Gene Patents in Court, Biopolitical TimesApril 7th, 2011A Federal Court of Appeals panel heard oral arguments in the Myriad case, but gave no hint of its decision; either way, many expect it to go to the Supreme Court.
|NIH Ethics Advisory Committee Disbanded, Biopolitical TimesSeptember 30th, 2010The abrupt cancellation of the Secretary's Advisory Committee on Genetics, Health, and Society is a disquieting development.|
|Of geese and genes, Biopolitical TimesSeptember 2nd, 2010The Financial Times publishes an argument for a "pre-competitive commons."
|Patent Happenings, Biopolitical TimesJuly 7th, 2010The pace of news on legal challenges to patents on human genes is quickening.
|Stem cells, human genes, and patents, Biopolitical TimesMay 14th, 2010A recent ruling on a stem cell patent is similar with concurrent challenges to patents on human genes related to breast cancer.|
|Gene Patents on CBS's "60 Minutes", Biopolitical TimesApril 2nd, 2010This Sunday, the long-running American television news show will air a segment on the debate over human gene patents.|
|Public Interest Group Praises Court Decision that Human Genes Cannot Be PatentedCenter for Genetics and Society Calls Ruling a Victory for Patients, Consumers and Responsible ResearchMarch 30th, 2010CGS welcomed yesterday's District Court decision invalidating patents on genes associated with breast and ovarian cancer, which ruled that human genes cannot be patented because they are products of nature|
|Judge Invalidates Human Gene Patent[Quotes CGS's Jesse Reynolds], The Associated PressMarch 29th, 2010In a ruling with potentially far-reaching implications for the patenting of human genes, a judge on Monday struck down a company's patents on two genes linked to an increased risk of breast and ovarian cancer.|
|IP lawyers defend IP, Biopolitical TimesNovember 17th, 2009On human gene patents, intellectual property lawyers in Australia take a firm stance--apparently a stronger position than that of the biotech industry.|
|Battle Over Human Gene Patents Builds, Biopolitical TimesOctober 28th, 2009A key government committee, a progressive news show, and a federal judge are all reconsidering human gene patents.|
|Public interest groups support groundbreaking challenge to human gene patentsCenter for Genetics and Society, Pro-Choice Alliance for Responsible Research, other organizations file brief backing lawsuitSeptember 1st, 2009Public interest, social justice, and women’s health advocates filed a "friend of the court" brief in support of a groundbreaking lawsuit by the American Civil Liberties Union and Public Patent Foundation challenging the constitutionality of human gene patents.|
|Gene Patent Lawsuit Draws Comments, Biopolitical TimesAugust 19th, 2009The legal challenge to gene patents is the impetus for a new article by CGS staffers Jesse Reynolds and Marcy Darnovsky.
|23andMe Gets Into the Breast Cancer Testing Business, Biopolitical TimesFebruary 23rd, 2009Google-backed 23andMe, a leader in the recreational genetics sector, has added a new service: telling its customers whether they have a genetic variant that may significantly increase their chance of developing breast and ovarian cancer. |
|Africans’ DNA could be abused, The Times (South Africa)February 14th, 2009South African researchers and traditional leaders fear US scientists will soon start patenting the genes of local ethnic groups, many of whom have donated blood samples as part of a worldwide genome-mapping project. |
|Hwang to Back His Own Inventions, The Korea TimesJanuary 12th, 2009Getting a shot at redemption, Hwang's colleague at the Sooam Biotech Research Center confirmed that Seoul National University had handed over the intellectual property rights for Hwang's claimed inventions in human stem cell research to H-Bion.|
|Letting Sleeping Dogs Lie, Biopolitical TimesJune 12th, 2008The leadership of the California stem cell research agency has commissioned a new economic report. Any realistic economic analysis may not be an effective shield in Sacramento during a period of drastic budget cuts, and by reviving past controversy, revisiting the economic argument may backfire.|
|Dog Cloning and Intellectual Property, Biopolitical TimesJune 5th, 2008In the minor flurry of stories last month about an on-line auction of dog cloning services, the issue of intellectual property was completely overlooked. That’s too bad, since the cloning business, like so many others, is best understood by following the money.|
|Unseen Rise of ‘Body Shopping’, The Sunday TimesApril 20th, 2008Good science can’t be rushed, and the commercialisation of biotechnology needs proper examination. The problem is that parliament is too busy arguing about God to pay much attention.|
|Another Bill to Reform the California Stem Cell Research Program, Biopolitical TimesMarch 4th, 2008For the fourth year in a row, the Democratic chair of the California Senate Health Committee, currently Sheila Kuehl, and her Republican colleague, George Runner, have introduced a bill to address some of the flaws in the California stem cell research program.|
|Stem-cell Firms Resisting Cash LureInstitute Offers Grants with Strings Attached, San Jose Mercury NewsDecember 20th, 2007Although companies now have a chance for the first time in the institute's three-year history to apply for its money, they may wind up having to share some of their revenue and research. And that is giving some companies second thoughts about participating.|
|A State Bill Passes, a Federal One Stalls, Biopolitical TimesSeptember 14th, 2007A California bill that would require the labeling of meat or dairy produced from cloned animals has passed the state Legislature. Meanwhile, a federal bill to permit generic biotechnology medicines has stalled again.|
|Don't Bite the Hand that Feeds You, Biopolitical TimesAugust 3rd, 2007Given the magnitude of Keirstead's promotional activities, his undisclosed personal financial interest, and his own statement of clinical trials "in about a year" back in 2002, his pronouncements on the timeline for embryonic stem cell trials should receive a great deal of skepticism.|
|Gene Patent Bill, Biopolitical TimesMay 18th, 2007The Genomic Research and Accessibility Act - aiming to curb the gold rush on patenting human genes - is making its way through Congress.|
|Federal Bill to Ban Patents on Human Genes IntroducedGenetic CrossroadsApril 30th, 2007The "Genomic Research and Accessibility Act" would prohibit future patents on human genes, a practice that has given "private corporations, universities, and even the federal government…a monopoly on significant sections of the human genome."|
|UK's HFEA Lowers the Bar, Again, Biopolitical TimesApril 30th, 2007The Human Fertilization and Embryology Authority - Britain's regulatory body for reproductive and genetic technologies - has just given the green light for IVF embryos to be screened for the "breast cancer genes." But besides this lowering of the bar in expanding PGD's use, this also highlights two roles played by government in promoting what some call a "new eugenics."|
|CGS letter on California's SB771April 4th, 2007CGS supports, if amended, SB771. We are concerned that the bill as currently written does not go far enough to protect Californians from potentially unfair pricing practices.|
|Restrictive Stem Cell Patents Overturned, Biopolitical TimesApril 4th, 2007The licensing arm of the University of Wisconsin has long been criticized for its patents in embryonic stem cell research. Earlier this week, a federal agency agreed with these sentiments, and invalidated its stem cell patents.|
|Genetic justice, industry style, Biopolitical TimesMarch 19th, 2007The issues raised by the intertwining of law and human biotechnologies are often technically and socially complex. What's a busy jurist to do?|
|Neurolaw, Biopolitical TimesMarch 13th, 2007Should courts be in the business of deciding when to mitigate someone's criminal responsibility because his brain functions improperly, whether because of age, in-born defects or trauma?|
|Bill to End Human Gene Patents Introduced in HouseGenetic CrossroadsFebruary 28th, 2007Hoping to end patents on human genes and genetic material, Representatives Xavier Becerra (D-CA) and Dave Weldon (R-FL) have introduced HR 977, the Genomic Research and Accessibility Act.|
|Patenting Life, New York TimesFebruary 13th, 2007YOU, or someone you love, may die because of a gene patent that should never have been granted in the first place. Sound far-fetched? Unfortunately, it’s only too real.|
|A Penny on the Dollar, East Bay ExpressJanuary 24th, 2007"The more details emerge about Proposition 71, California's $3 billion stem-cell research project, the more it all looks like a big lie that will cost us billions of dollars more than we were told."|
|Stem Cell Reality Check, Capitol WeeklyJanuary 23rd, 2007A University of California Berkeley economics professor has done an analysis of the financial returns likely to come to California from stem cell research--and he said they will likely be a small fraction of what proponents" say.|
|The Trouble with Tissues, Biopolitical TimesNovember 30th, 2006It's not surprising that, according to a recent poll, people are concerned that personal tissue samples could be used for cloning, the derivation of stem cell lines, or the development profitable products without the donor sharing in the rewards.|
|Editorial: Cellular mutationSacramento BeeJune 2nd, 2006"In her latest effort to reform California's $3 billion stem cell research institute, state Sen. Deborah Ortiz, D-Sacramento, has introduced SB 401, a proposed ballot measure that seeks to close gaps in Proposition 71..."|
|Opinion: The legal lock on stem cells, Los Angeles TimesApril 12th, 2006"CALIFORNIA'S $3-billion stem cell program has encountered repeated setbacks since it was approved by voters 17 months ago. Now it faces an entirely new and potentially even more worrisome challenge arising from two powerful patents..."|
|'Research misbehavior', NewsdayMarch 13th, 2006"While the recent scandal involving the now discredited research of South Korean scientist Hwang Woo-Suk was an extreme example, ethicists say less flagrant questionable behavior in the halls of science often goes undetected or ignored."|
|U.S. Stem Cell Researcher Rebuked, Washington PostFebruary 11th, 2006"Investigators at the University of Pittsburgh have concluded that Pitt faculty member and stem cell researcher Gerald P. Schatten committed "research misbehavior" by seeking personal, professional and financial gains from research..."|
|Stem cell profit rules urgedSacramento BeeJanuary 24th, 2006"Biotech companies that commercialize taxpayer-funded stem cell research would have to plan to sell the drugs at the "lowest available U.S. commercial price" to low-income Californians, a task force recommended Monday..."|
|Editorial: Science and DemocracySan Francisco ChronicleNovember 13th, 2005"Now that California taxpayers know that the $3 billion ($6 billion with debt service) that they voted in 2004 to spend on stem-cell research may possibly be an outright grant of money for research rather than an investment, does it make a difference?"|
|Stem-Cell WonderlandWill cures be affordable to all?, Sacramento News & ReviewOctober 20th, 2005Ralph Brave reviews the tensions between the realities and promises of stem cell research and California's Proposition 71. In a sidebar, he touches on the importance of intellectual property rights.|
|Editorial: Save the Stem CellsThe Daily CalifornianOctober 4th, 2005UC Berkeley's student newspaper: "[T]he state legislature may make a big mistake by adopting provisions of the 1980 Bayh-Dole Patent and Trademark Act.... But Bayh-Dole benefits industry more than it helps universities."|
|Stem cell_s shell game?Capitol WeeklySeptember 22nd, 2005"The biggest question surrounding stem cell research in California right now isn_t whether it will eventually cure devastating health problems. It_s what happened to the billion dollars."|
|Editorial: Stem cell propertySacramento BeeAugust 29th, 2005"California needs to have some measure of control over the intellectual property it has agreed to finance.... [balancing] the public interest with the realities that California is competing against other countries to advance stem cell research."|
|Onward, Christian LawyersSan Francisco WeeklyJuly 27th, 2005The lawsuits filed against California's stem cell institute by anti-abortion groups may be a blessing in disguise, forcing the institute to tackle basic organizational issues.|
|Stem cell issues near a boil, Sacramento BeeJune 6th, 2005Laura Mecoy summarizes the challanges and issues facing California's new stem cell program: a lawsuit filed by conservative opponents, a reform proposal in the Senate, and "a controversial new way to finance the agency until the legal battles are over."|
|Stem-cell oversight bill is criticized, San Jose Mercury NewsMay 24th, 2005"The board overseeing California's new $3 billion stem-cell institute on Monday denounced a bill in the Legislature intended to strengthen state oversight of the program, claiming the measure would cripple its research and its ability to help the sick."|
|Editorial: Rogue operatorSacramento BeeMay 22nd, 2005The California stem cell research "institute's oversight board needs to demonstrate some oversight of Klein. They also should look for ways to compromise with Ortiz, so this institute can get on with the job of finding lifesaving therapies."|
|Opinion: Stem Cell Agency on Errant Fast Track, Los Angeles TimesMay 16th, 2005Times' columnist Michael Hiltzik writes that the "California Institute for Regenerative Medicine has behaved not like the state agency it is, but with the arrogance of a private corporation that happens to be playing with the taxpayers' cash."|
|Stem-cell research: After the gold rush, NatureApril 7th, 2005"California's voters have authorized the spending of $3 billion over the next decade on stem-cell research. But will this bonanza bring threats as well as opportunities?"|
|Opinion: The opaque petri dish, Sacramento BeeJanuary 9th, 2005"[ICOC Chair Robert] Klein and his supporters are offering a 'trust us' argument, which Californians may have trouble swallowing. Ratepayers heard the same thing when business leaders and state lawmakers deregulated electricity."|
|Second-guessing Prop. 71, San Francisco Bay GuardianDecember 22nd, 2004The weekly Bay Guardian takes on Sen. Ortiz, the San Francisco Chronicle, and the Los Angeles Times for not voicing their concerns over California's Proposition 71 before the election.|
|Experts discuss Prop. 71 ethics, San Jose Mercury NewsNovember 10th, 2004At a conference of the California Healthcare Institute, state Sen. Deborah Ortiz - a key supporter of California's Proposition 71 - said she will be monitoring its implementation for conflicts of interest and to ensure the state benefits from research.|
|The rush to research, The Press EnterpriseNovember 6th, 2004"The victory [of Prof. 71] spurred predictions that the law will woo the world's top talent in this new field and accelerate advances in treating such diseases.... Others, however, are not convinced."|
|Rivals charge Prop. 71 conflict, Sacramento BeeOctober 20th, 2004"Stem cell initiative opponents on Tuesday demanded that the Proposition 71 campaign release the financial holdings of its supporters amid new reports that one of the measure's advocates could profit from the $3 billion bond measure."|
|Stem cell measure brings foes together[Quotes CGS's Richard Hayes], San Jose Mercury NewsOctober 20th, 2004A "respected group of liberals" are opposing California's Proposition 71, "concerned about the role of private biotech companies, the rights of women whose eggs would be harvested and the long-term consequences of manipulating life."|
|Foes: Profit drives stem cell measure, Sacramento BeeOctober 16th, 2004"The campaign to create the nation's largest-ever state-funded scientific research program is finding its strongest financial support among the multimillionaire investors critics say could profit from the $3 billion bond measure for stem cell studies."|